Lytgobi (Futibatinib)

 Lytgobi (futibatinib) is a kinase inhibitor used for the treatment of adult patients with previously treated, unresectable (cannot be removed by surgery), locally advanced or metastatic intrahepatic cholangiocarcinoma (a type of liver cancer) harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements.

Note: The above indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR). Continued approval for this use may depend on confirming and showing the clinical benefits in a follow-up trial(s).

Recommended Dosage: 

The recommended dosage of Lytgobi is 20 mg (five 4 mg tablets) taken orally once daily until there is evidence of disease progression or unacceptable toxicity. Take the oral tablets with or without food at approximately the same time each day. Swallow oral tablets whole. It is not advisable to crush, chew, split, or dissolve tablets.

If the patient misses a scheduled dose of this therapeutic drug for more than 12 hours or if vomiting occurs, resume dosing with the very next scheduled dose.  

• Treatment with Futibatinib 4 mg tablets may be responsible for causing eye problems, including eye irritation or vision changes. Regular eye exams are necessary during treatment. In case any vision complications occur, contact your healthcare provider (HCP) immediately for further evaluation and possible adjustments.
• This therapeutic drug can increase the levels of phosphate in the blood. This may lead to mineral buildup in soft tissues. Regular blood tests are needed to monitor the levels of phosphate. Treatment may be adjusted in case of detection of hyperphosphatemia.
• Treatment with this medicine may cause harm to an unborn baby. Do not use this medicine during pregnancy unless urgently required. Women of reproductive potential should use an effective contraception method during treatment and for some time after stopping treatment to prevent probable consequences to the fetus.
• This medicine may pass into breast milk and may affect a nursing infant. It is not recommended to use this medicine while breastfeeding. Consult your healthcare provider (HCP) about alternative treatment options before using this treatment.
• Male as well as female patients should use an effective and appropriate contraception method during treatment with Lytgobi 4 mg tablets. This is to prevent pregnancy because of potential risks to the unborn child from the medicine.
• The safety as well as the effectiveness of this therapeutic drug in children has not been established. It is not recommended to use this oral medicinal product in pediatric patients under 18 years without careful evaluation and approval by a healthcare provider (HCP).
• Patients who are elderly may be more sensitive to the effects of Futibatinib. Dosage adjustments or monitoring for side effects are necessary. Healthcare providers (HCPs) should carefully assess both the benefits and risks for geriatric patients before starting this treatment.

What documents are required to import LYTGOBI to India?

LYTGOBI (futibatinib) tablets can be imported by patients or government hospitals in the patients’ name only. 

The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
  
• Patients diagnostic reports
  
• Patient ID proof (issued by the government of India)

How does the order get confirmed?

The order will be confirmed only after the receipt of:

• A valid prescription from the Doctor
  
• Import permit if applicable

Is LYTGOBI available in India?

LYTGOBI (futibatinib tablet) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator, providing input

• On availability of Lytgobi in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.)
  
• On availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
  
• Medicine Price.
  
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
  
• Ensuring 100% transparency.

LYTGOBI can be made available to patients, doctors, and hospitals in Mumbai, Goa, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune, and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

IPN (Indian Pharma Network) can facilitate the supply of LYTGOBI (a prescription medicine) to all locations in the world and India after fulfilling the legal requirements (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Lytgobi 4 mg Tablet price in India. 

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

What is the Generic Name for the trade name drug Lytgobi®?

Futibatinib is the Generic Name for the trade name drug Lytgobi®.

What is the Manufacturer’s Name of Lytgobi®?

Lytgobi® is manufactured by Taiho Pharmaceutical Co., Ltd.

Is Lytgobi® approved by the FDA?

No, Lytgobi® is approved by the FDA. Date of first Approval: September 30, 2022.

What is the dosage and form of Lytgobi® supplied?

Lytgobi® is supplied in Tablets: 4 mg for oral administration. This oral medicine can only be obtained with a prescription.

What are the most common side effects of Lytgobi®? 

The most common side effects of Lytgobi® are dry eye, nail toxicity, constipation, musculoskeletal pain, diarrhea, stomatitis, fatigue, dry mouth, alopecia, abdominal pain, urinary tract infection, dry skin, arthralgia, dysgeusia, nausea, decreased appetite, vomiting and palmar-plantar erythrodysesthesia syndrome.

How much does the Lytgobi® 4 mg Tablet cost in India?

Prices of Lytgobi may fluctuate over time due to market dynamics and regulatory changes. To get the most accurate and latest details on Lytgobi 4 mg tablet cost in India, please call/WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

Can Lytgobi® 4 mg Tablets be available in SAARC countries? 

Apart from Gulf countries, Lytgobi® 4 mg can be available in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). Indian Pharma Network (IPN) can help facilitate the legal supply of Lytgobi® tablets in these countries. We help ensure legal access to this therapeutic drug through our reliable channels.

Is it safe to buy Lytgobi® 4 mg Tablets online in India?

Yes, one can buy Lytgobi 4 mg online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in their country. We can help facilitate the supply of Lytgobi® oral tablets through legal channels. 

What are the storage conditions of Lytgobi® 4 mg tablets?

Store tablets of Lytgobi® at room temperature 20 to 25°C (68 to 77°F); excursions permitted between 15 and 30°C (59 to 86°F).